H2020-JTI-IMI2-2014-02-single-stage
H2020-JTI-IMI2-2014-02-single-stage
- Programme
- H2020
- Funded projects (dataset)
- 8
- EU contribution (sum)
- €114,090,808
- Portal deadline
- —
Leading topic in historical projects: IMI2-2014-02-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- LSHTM2 coordinated
- DH1 coordinated
- FOHM1 coordinated
- HP HEALTH SOLUTIONS GERMANY GMBH1 coordinated
- INSERM1 coordinated
- SVA1 coordinated
- VIBALOGICS1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- INMI3 topic projects
- Janssen Vaccines (f.k.a. Crucell Holland B.V.)3 topic projects
- UOXF3 topic projects
- CHU Bordeaux2 topic projects
- EMERGENCY ONG ONLUS2 topic projects
- INSERM TRANSFERT SA2 topic projects
- UBx2 topic projects
- Leiden University Medical Center1 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- 2 shared
- 2 shared
- CHU Bordeaux · UOXF2 shared
FR ↔ UK
- 2 shared
- 2 shared
- 2 shared
- CHU Bordeaux · UBx2 shared
FR ↔ FR
- CHU Bordeaux · LSHTM2 shared
FR ↔ UK
- 2 shared
- 2 shared
- 2 shared
- 2 shared
- INSERM · INSERM TRANSFERT SA2 shared
FR ↔ FR
- 2 shared
- 2 shared
- INMI · EMERGENCY ONG ONLUS2 shared
IT ↔ IT
- CHU Bordeaux · INSERM2 shared
FR ↔ FR
- 2 shared
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 8.25
- Median orgs / project
- 6.5
- Min / max orgs
- 3 – 18
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- France12
- United Kingdom10
- Italy9
- Germany7
- United States4
- Netherlands4
- Denmark3
- Sweden3
- Switzerland3
- Finland2
- Sierra Leone2
- Belgium2
- Gabon1
- Czechia1
- Ireland1
- Senegal1
- Burkina Faso1
Organization types
- university19 orgs · 25 rows
- research_institute10 orgs · 16 rows
- company8 orgs · 11 rows
- other7 orgs · 8 rows
- sme5 orgs · 5 rows
- public_body1 orgs · 1 rows
Topics in funded projects
- IMI2-2014-02-01IMI2-2014-02-01· 3 projects
- IMI2-2014-02-05IMI2-2014-02-05· 3 projects
- IMI2-2014-02-02IMI2-2014-02-02· 1 projects
- IMI2-2014-02-04IMI2-2014-02-04· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| EBOVAC1 Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854 | H2020 | €58,336,885 |
| EBOVAC2 Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861 | H2020 | €22,790,820 |
| EBODAC Communication strategy and tools for optimizing the impact of Ebola vaccination deployment – Sofia ref.: 115847 | H2020 | €20,328,856 |
| EbolaMoDRAD Ebola Virus: Modern Approaches for developing bedside Rapid Diagnostics – Sofia ref.: 115843 | H2020 | €4,300,935 |
| VSV-EBOVAC Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842 | H2020 | €3,887,260 |
| FILODIAG Ultra-Fast Molecular Filovirus Diagnostics - Sofia ref.: 115844 | H2020 | €2,260,105 |
| Mofina Mobile Filovirus Nucleic Acid Test – Sofia ref.: 115848 | H2020 | €1,162,622 |
| EBOMAN Manufacturing and Development for Rapid Access Ebola Vaccine (EBOMAN) – Sofia ref.: 115850 | H2020 | €1,023,325 |